Overview

Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer

Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether sequential neo-adjuvant chemotherapy plus surgery followed by Capecitabine could achieve additional benefits over traditional postoperative chemotherapy. In the study group, patients that do not achieve pathological complete response(pCR) will receive sequential neo-adjuvant chemotherapy followed by Capecitabine. In the control group, patients will be treated with postoperative adjuvant chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
First Hospital of Jilin University
The First Hospital of Jilin University
Collaborators:
Baotou Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University
First Hospital of China Medical University
Qingdao University
The Second Affiliated Hospital of Harbin Medical University
Treatments:
Capecitabine